Pfizer Kicks Off Big Pharma Earnings. Cost-Cutting Will Be Key. — Barrons.com
By Josh Nathan-Kazis Pfizer is set to report fourth-quarter earnings on Tuesday morning, after a year of big deals and disappointing stock performance. Analysts expect the company to report a loss of $0.18 a share for the quarter, and revenue of $14.4 billion, according to FactSet. Pfizer issued a reset in December, laying out guidance for 2024 that was well below what analysts had expected, and highlighting a $4 billion cost savings program. It said it expects adjusted diluted earnings of between $2.05 and $2.25 this year, and revenue between $58.5 billion and $61.5 billion. The consensus estimate is $2.27 per share. Pfizer shares are down 4.9% so far this year, and 37.1% over the past 12 months. The company made a string of major deals in recent years, notably the $43 billion acquisition of the cancer-focused biotech Seagen, and the $11 billion acquisition of Biohaven Pharmaceuticals in 2022. Those […]
Pfizer Kicks Off Big Pharma Earnings. Cost-Cutting Will Be Key. — Barrons.com Read Post »